Moreover, in another clinical trial, it was found that AP-related C3 activation contributes to hepatic inflammation in NASH; deposition of properdin, a positive regulator of the AP, and of the C3 activation product C3c, positively correlated with liver inflammation level in NASH (14). Here, CFP is linked to metabolic dysfunction-associated steatohepatitis.